公开(公告)号：EP2134344A1

公开(公告)日：2009-12-23

申请号：EP08726976.7

申请日：2008-03-19

申请人： Schering Corporation

发明人： VELTRI, Enrico, P. ,  STRONY, John, T. ,  CHINTALA, Madhu

IPC分类号： A61K31/443 ,  A61P9/10

CPC分类号： A61K31/443

摘要： Disclosed are methods of preventing adverse clinical events in a patient undergoing a percutaneous coronary intervention procedure or a peripheral percutaneous interventional procedure comprising administering a therapeutically effective amount of a thrombin receptor antagonist, such as SCH 530348, to the patient. Administration of a loading dose of about 40 mg of SCH 530348 in as little as one hour prior to the procedure can result in therapeutically effective levels of platelet aggregation.

公开(公告)号：EP1701953A1

公开(公告)日：2006-09-20

申请号：EP05705212.8

申请日：2005-01-07

申请人： SCHERING CORPORATION

发明人： THIRUVENGADAM, Tiruvettipuram, K. ,  WU, Wenxue ,  WANG, Tao ,  CHIU, John, S. ,  BOGDANOWICH-KNIPP, Susan ,  PAVLOVSKY, Anastasia ,  GREENLEE, William, J. ,  GRAZIANO, Michael, P. ,  KOSOGLOU, Teddy ,  CHINTALA, Madhu ,  CHACKALAMANNIL, Samuel

IPC分类号： C07D405/06 ,  C07D307/00 ,  C07D213/00

CPC分类号： C07D417/14 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D405/06 ,  C07D405/14 ,  C07D413/14

摘要： A crystalline polymorph of a bislulfate salt of a thrombin receptor antagonist compound, which exhibits a powder x-ray diffraction profile substantially the same as that shown in FIG. 1, or which exhibits a differential scanning calorimtery profile substantially the same as that shown in FIG. 3, and is represented by the formula for Compound 2: Chemical formula should be inserted here as it appears on the abstract in paper form. and processes for preparing Compound 2 are disclosed. Pharmaceutical compositions comprising the polymorph of the bisulfate salt and at least one excipient or carrier, and methods of using the polymorph of Compound 2 to treat a variety of physiological disorders, such as thrombosis, are also disclosed.

公开(公告)号：EP1751144B1

公开(公告)日：2008-08-27

申请号：EP05755642.5

申请日：2005-05-25

申请人： Schering Corporation

发明人： CHELLIAH, Mariappan, V. ,  CHACKALAMANNIL, Samuel ,  XIA, Yan ,  CLASBY, Martin, C. ,  GREENLEE, William, J. ,  WANG, Yuguang ,  VELTRI, Enrico, P. ,  WU, Wenxue ,  GRAZIANO, Michael, P. ,  KOSOGLOU, Teddy ,  CHINTALA, Madhu

IPC分类号： C07D405/08 ,  C07D493/04 ,  A61K31/443 ,  A61K31/4433 ,  A61P9/00 ,  A61P25/28 ,  A61P11/00

CPC分类号： C07D493/04 ,  C07D405/06

摘要： A compound represented by the structural formula (Chemical formula should be inserted here as it appears on abstract in paper form) and pharmaceutically acceptable salts and solvents thereof is disclosed, wherein: the single-dashed line between the ring carbons to which R10 and R34 are attached represents either a single bond or a double bond; the double-dashed line between X and the carbon to which Y is attached represents either a single bond or an absent bond; X is -O- or -NR6- when the double-dashed line represents a single bond; X is H, -OH or -NHR20 when the double-dashed line represents an absent bond; and other parameters are as defined herein. Also disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor antagonists and binders to cannabinoid receptors.

公开(公告)号：EP1751144A1

公开(公告)日：2007-02-14

申请号：EP05755642.5

申请日：2005-05-25

申请人： SCHERING CORPORATION

发明人： CHELLIAH, Mariappan, V. ,  CHACKALAMANNIL, Samuel ,  XIA, Yan ,  CLASBY, Martin, C. ,  GREENLEE, William, J. ,  WANG, Yuguang ,  VELTRI, Enrico, P. ,  WU, Wenxue ,  GRAZIANO, Michael, P. ,  KOSOGLOU, Teddy ,  CHINTALA, Madhu

IPC分类号： C07D405/08 ,  C07D493/04 ,  A61K31/443 ,  A61K31/4433 ,  A61P9/00 ,  A61P25/28 ,  A61P11/00

CPC分类号： C07D493/04 ,  C07D405/06

摘要： A compound represented by the structural formula (Chemical formula should be inserted here as it appears on abstract in paper form) and pharmaceutically acceptable salts and solvents thereof is disclosed, wherein: the single-dashed line between the ring carbons to which R10 and R34 are attached represents either a single bond or a double bond; the double-dashed line between X and the carbon to which Y is attached represents either a single bond or an absent bond; X is -O- or -NR6- when the double-dashed line represents a single bond; X is H, -OH or -NHR20 when the double-dashed line represents an absent bond; and other parameters are as defined herein. Also disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor antagonists and binders to cannabinoid receptors.

摘要翻译： 公开了由结构式（化学式应当插入本文作为摘要以纸形式出现）的化合物及其药学上可接受的盐和溶剂，其中：R10和R34所代表的环碳之间的单点划线 连接表示单键或双键; X与Y所连接的碳之间的双点划线表示单键或无键; 当双虚线表示单键时，X是-O-或-NR6-; 当双虚线表示无键时，X是H，-OH或-NHR20; 和其他参数如本文所定义。 还公开了含有所述化合物及其作为凝血酶受体拮抗剂和大麻素受体结合剂的用途的药物组合物和组合。

公开(公告)号：EP1682140A2

公开(公告)日：2006-07-26

申请号：EP04810675.1

申请日：2004-11-09

申请人： SCHERING CORPORATION

发明人： CHACKALAMANNIL, Samuel ,  CLASBY, Martin, C. ,  GREENLEE, William, J. ,  WANG, Yuguang ,  XIA, Yan ,  VELTRI, Enrico, P. ,  CHELLIAH, Mariappan, V. ,  WU, Wenxue ,  GRAZIANO, Michael, P. ,  KOSOGLOU, Teddy ,  CHINTALA, Madhu

IPC分类号： A61K31/4525 ,  A61K31/343 ,  A61P9/00 ,  A61P29/00 ,  A61P11/00 ,  A61P35/00 ,  A61P25/28 ,  A61P13/12

CPC分类号： A61K31/4525 ,  A61K31/343 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D405/06 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

摘要： A method of treating a therapeutic condition comprising administering to a mammal in need of such treatment an effective amount of at least one compound of the formulas: or a pharmaceutically acceptable isomer, salt, solvate or co-crystal form thereof, wherein the substituents are as defined in the specification, wherein said therapeutic condition is a cardiovascular or circulatory disease or condition, an inflammatory disease or condition, a respiratory tract or disease or condition, cancer, acute renal failure, astrogliosis, a fibrotic disorder of the liver, kidney, lung or intestinal tract, Alzheimer's disease, diabetes, diabetic neuropathy, rheumatoid arthritis, neurodegenerative disease, neurotoxic disease, systemic lupus erythematosus, multiple sclerosis, osteoporosis, glaucoma, macular degeneration, psoriasis, radiation fibrosis, endothelial dysfunction, a wound or a spinal cord injury, or a symptom or result thereof. Combination therapy with other therapeutically effective agents is also disclosed.